Latest Conference Articles

September 20th 2020, 12:06am

ESMO Congress: Gynecologic Cancers

Dostarlimab showcased durable antitumor activity in patients with advanced or recurrent DNA mismatch repair deficient and proficient endometrial cancer, with a notable disease control rate and a promising safety profile.

September 19th 2020, 11:48pm

ESMO Congress: Breast Cancer

Treatment with sacituzumab govitecan led to a 59% reduction in the risk of disease progression or death compared with physician’s choice of single-agent chemotherapy in patients with previously treated metastatic triple-negative breast cancer.

September 19th 2020, 10:49pm

ESMO Congress: GU Cancers

Sacituzumab govitecan-hziy continued to showcase significant activity with favorable tolerability in heavily pretreated patients with metastatic urothelial carcinoma who progressed on both platinum-based chemotherapy and checkpoint inhibition.

September 19th 2020, 9:37pm

ESMO Congress

Spartalizumab plus dabrafenib did not significantly improve progression-free survival over dabrafenib/trametinib in patients with untreated BRAF V600-mutant unresectable or metastatic melanoma.

September 19th 2020, 9:30pm

ESMO Congress: GI Cancers

The novel broad-spectrum KIT and PDGFRα inhibitor ripretinib continued to demonstrate clinically meaningful benefit as a fourth- or later-line treatment for patients with advanced gastrointestinal stromal tumors.

September 19th 2020, 8:30pm

Although the SOLAR-1 trial did not cross the prespecified O’Brien-Fleming efficacy boundary in postmenopausal patients with PIK3CA-mutant, hormone receptor–positive, HER2-negative advanced breast cancer, alpelisib and fulvestrant nevertheless prolonged the median OS.

September 19th 2020, 8:19pm

ESMO Congress

Early findings from a phase II efficacy and safety study may be the first step in developing a definitive rationale for sequencing targeted therapies and immunotherapies in patients with metastatic melanoma.

September 19th 2020, 7:14pm

ESMO Congress: GU Cancers

Neither monotherapy with durvalumab or combination treatment with durvalumab plus tremelimumab met co-primary end points of overall survival vs chemotherapy for the treatment of metastatic urothelial cancer.

September 19th 2020, 7:00pm

ESMO Congress: GI Cancers

As first-line therapy for patients with microsatellite instability-high and/or mismatch-repair deficient metastatic colorectal cancer, pembrolizumab improves quality of life compared with standard chemotherapy.

September 19th 2020, 6:20pm

ESMO Congress: GU Cancers

The benefits conferred by the combination of nivolumab and ipilimumab for the first-line treatment of advanced renal cell carcinoma remained durable after 4-year follow-up compared with treatment with sunitinib.

September 19th 2020, 6:15pm

ESMO Congress: GI Cancers

Improvements in disease-free survival and progression-free survival were observed in patients with progressive pancreatic or midgut neuroendocrine tumors whose frequency of dosing for lanreotide Autogel was increased from 120 mg every 28 days to every 14 days.

September 19th 2020, 5:52pm

ESMO Congress

Safety and preliminary antitumor activity with the bispecific antibody RO7122290 alone or in combination with atezolizumab demonstrated preliminary antitumor activity and was safe for the treatment of patients with advanced solid tumors.

September 19th 2020, 5:38pm

ESMO Congress: Gynecologic Cancers

The investigative PD-1 inhibitor balstilimab as a single agent and combined with the CTLA-4 inhibitor zalifrelimab showed promising objective response rates, regardless of PD-L1 expression, and a tolerable safety profile in patients with recurrent/metastatic cervical cancer.

September 19th 2020, 4:58pm

ESMO Congress: Breast Cancer

Although atezolizumab did not improve pathological complete response when added to carboplatin and nab-paclitaxel, the immunotherapy increased the pCR by 10% or more in “immune-rich” groups with high-risk and locally advanced triple-negative breast cancer, and also turned PD-L1 negative tumors positive in most immunotherapy-treated patients.

September 19th 2020, 4:30pm

ESMO Congress: GU Cancers

The combination of nivolumab and cabozantinib led to a 49% reduction in the risk of disease progression or death, while also significantly improving overall survival and doubling objective response rate, compared with sunitinib in the first-line treatment of patients with advanced renal cell carcinoma.

September 19th 2020, 4:24pm

ESMO Congress: Lung Cancer

Neoadjuvant durvalumab achieved a satisfactory complete surgical resection rate in patients with resectable non–small cell lung cancer, demonstrating preliminary promise for this treatment strategy.

September 19th 2020, 4:12pm

ESMO Congress: Lung Cancer

One preoperative injection of atezolizumab was considered safe and induced major pathological responses in select patients with resectable non–small cell lung cancer.

September 19th 2020, 3:49pm

ESMO Congress: Head and Neck Cancer

Three-year follow-up data for the phase 2 study of the first-in-class inhibitor of apoptosis protein antagonist, xevinapant, in combination with standard cisplatin-based concomitant fractionation chemoradiation therapy reduced the risk of mortality by half compared with CRT alone in patients with locally advanced squamous cell carcinoma of the head and neck.

September 18th 2020, 10:15pm

ESMO Congress: GU Cancers

Frontline maintenance treatment with avelumab plus best supportive care improved both progression-free and overall survival compared with BSC alone across prespecified subgroups of patients with advanced or metastatic urothelial carcinoma that has not progressed on first-line platinum-based chemotherapy.

September 18th 2020, 10:08pm

ESMO Congress: GU Cancers

Despite observed responses, induction therapy with avelumab prior to standard of care gemcitabine/carboplatin fails to sustain clinically meaningful efficacy and is not an adequate strategy for the first-line treatment for patients with metastatic urothelial carcinoma.